Science | Nature | Cell | View More
Bioactive Products
Anticancer Compound Library
A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research
Catalog No: B91 Anticancer Compound Library
Screening Details
Size: 1mg/well * 674 Compounds
2mg/well * 674 Compounds
Cat. No. Information
CFN98158 Scopolamine butylbromide

Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55.3 ± 4.3 nM, it possesses anticholinergic, and anti-tumor effects, it used as an abdominal-specific antispasmodic agent. Scopolamine butylbromide is effective in preventing succinylcholine-induced bradycardia in infants and children.
CFN98337 Geniposidic acid

Geniposidic acid is an effective anticancer and radioprotection agent, used to treat inflammation, jaundice and hepatic disorders. It has anti-atherosclerotic effects, can protect vascular endothelium and reverse plaque formation in an atherosclerotic model. Geniposidic acid has effects on the expression of MRP2 and BSEP in BRL-3A cells after FXR gene silencing mediated by si RNA.
CFN98338 Ervamycine

11-Methoxytabersonine(Ervamycine) exhibits inhibitory effects against five human cancer cell lines , with IC(50) values comparable to those of cisplatin and vinorelbine.
CFN98348 7-Geranyloxy-6-methoxycoumarin

7-Geranyloxy-6-methoxycoumarin shows significant cytotoxicity against three cell lines (A549, SMMC-7721 and BALL-1).
CFN98167 Byakangelicol

Byakangelicol exhibits hepatoprotective activities on tacrine-induced cytotoxicity in Hep G2 cells, with EC(50) values of 112.7 +/- 5.35 microM. Byakangelicol may have therapeutic potential as an anti-inflammatory drug on airway inflammation, it can inhibit IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, it also can inhibit P-gp expressed. Byakangelicol shows a significant inhibition on the proliferation of cultured human tumor cells.